Mark E. Mcclure
Hills Road
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Incorporating frailty and disease severity into treatment decisions for older patients with ANCA-associated vasculitis.
Journal: Rheumatology (Oxford, England)
Published: August 15, 2025
Study protocol for a randomised, phase II, double-blind, experimental medicine study of obinutuzumab versus rituximab in ANCA-associated vasculitis: ObiVas.
Journal: BMJ open
Published: July 17, 2024
Temporal profiling of human lymphoid tissues reveals coordinated defense against viral challenge.
Journal: Nature immunology
Published: February 14, 2023
A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol.
Journal: Trials
Published: October 06, 2022
The Sound of Interconnectivity; The European Vasculitis Society 2022 Report.
Journal: Kidney international reports
Published: May 02, 2022
Alemtuzumab for refractory primary systemic vasculitis-a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE).
Journal: Arthritis research & therapy
Published: December 22, 2021
Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease.
Journal: Frontiers in immunology
Published: February 23, 2021
Extracorporeal membrane oxygenation for life-threatening ANCA-associated vasculitis with pulmonary haemorrhage.
Journal: Rheumatology (Oxford, England)
Published: December 03, 2020
Increasing incidence and improved survival in ANCA-associated vasculitis-a Danish nationwide study.
Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Published: March 25, 2020
Last Updated: 09/26/2026